The value of enhanced recovery after surgery in bariatric care: a systematic review and trial sequential meta-analysis confirming reduced length of stay, costs, and nursing-sensitive complications.

Surg Obes Relat DisMay 14, 2026 (epub)
Clinical ResearchGeneral Surgery

Fangqi Hu, Yueyue Yang, Yuze Sun et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and trial sequential meta-analysis evaluated the impact of enhanced recovery after surgery (ERAS) protocols on bariatric surgery outcomes. Analyzing 10 studies, including 8 randomized controlled trials, the findings revealed that ERAS significantly reduced hospital length of stay by .95 days and decreased postoperative vomiting incidence, supporting its implementation in bariatric care.

Key findings

  • ERAS reduced hospital length of stay by .95 days (95% CI: -1.40 to -.50; P < .01).
  • Postoperative vomiting incidence was lower in the ERAS group with an odds ratio of .35 (95% CI: .17 to .71; P < .01).
  • The analysis included 10 studies, comprising 8 RCTs and 2 cohort studies.

Why it matters

The implementation of ERAS protocols in bariatric surgery can lead to improved patient outcomes, including shorter hospital stays and fewer complications, which may enhance overall healthcare efficiency and patient satisfaction.

Source

PubMed · PMID 42236441

Published in Surg Obes Relat Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.